COMPANY PROFILE

Immutrin

Explore full profile

Immutrin conducts research into antibody immunotherapy for amyloidosis

Cambridge, United KingdomFounded 2019Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2026

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

At a glance

Status: Operational
Founded: 2019
Headquarters: Cambridge, United Kingdom
Employees: 16
Open positions: None listed
Dealroom signal: 54.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Drug Development, Immune System, Spinout, Rare Diseases, DT and LS, uk is8 life sciences, UKSU, UKSU2010, science-based
Client focus: b2b
Links: Website LinkedIn

Founder mafia, market maps, research and news connected to this company by Dealroom

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Mar 2026	$86M	$343M	F-Prime · Frazier Life Sciences · SR One · Cambridge Innovation Capital	↗
SPINOUTOther financing	Sep 2019	$0	—	Cambridge Enterprise · University of Cambridge	↗

Immutrin website traffic

Latest recorded traffic for Immutrin is 340 monthly website visits. Immutrin's team grew 166.7% over the past year.

Latest monthly visits340 1-year team growth+166.7%

Monthly website visitsJul 2026–Jul 2026

Summary metrics are public; monthly history is available with a demoCompare with peers →

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAmphista TherapeuticsNext-generation therapeutics for targeted protein degradation	Great Abington, United Kingdom	Operational	39	$82M	$212M
SBSilvia BioCellular analysis and media for biomanufacturing optimization.	Sheffield, United Kingdom	Operational
STScripta TherapeuticsAI-driven drug discovery modulating transcription factor activity	Oxford, United Kingdom	Operational
SISignaCorSignaCor is a clinical stage, drug development company, dedicated to the treatment of cardiac disease.	Belfast, United Kingdom	Operational
MLMitotype Precision LabsHigh-throughput mitochondrial assays for drug discovery	Sheffield, United Kingdom	Operational
RBRQ BiotechnologyMonoclonal antibodies for passive immunization against viruses	London, United Kingdom	Operational
MTMitoRx TherapeuticsBiotechnology company developing novel therapeutics that reverse mitochondrial dysfunction	Exeter, United Kingdom	Operational
SCScreenin3DMicrofluidic 3D screening of human cancerous tissue	Glasgow, United Kingdom	Operational